Trial Profile
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Novo Nordisk
- 13 Apr 2015 New trial record